Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2B Study of Selinexor (KPT-330), in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma Relapsing on Current Therapy

NCT04661137 is registered in ClinicalTrials.gov with Hackensack Meridian Health as lead sponsor.

NCT NCT04661137
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04661137 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2B Study of Selinexor (KPT-330), in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma Relapsing on Current Therapy
Lead sponsor
Hackensack Meridian Health
Phase
Phase 2
Overall status
Recruiting
Start date
March 16, 2021
Completion date
February 29, 2028
Enrollment
96 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma